Compare
Medicinova Inc vs Can-Fite BioPharma Ltd. vs Scienture Holdings, Inc. vs Mereo BioPharma Group plc
| Latest fiscal year | Medicinova Inc MNOV | Can-Fite BioPharma Ltd. CANF | Scienture Holdings, Inc. SCNX | Mereo BioPharma Group plc MREO |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $409.7K | $405.0K | $431.6K | $500.0K |
| Revenue growth (YoY) | n/a | -39.9% | +215.9% | n/a |
| Gross margin | n/a | n/a | 76.8% | n/a |
| Operating margin | n/m | n/m | n/m | n/m |
| Net margin | n/m | n/m | n/m | n/m |
| Net income | -$12.00M | -$9.83M | -$41.51M | -$41.88M |
| EPS (Diluted) | -$0.24 | -$5.97 | -$2.70 | -$0.05 |
| Operating cash flow | -$9.81M | -$8.95M | -$13.38M | -$30.97M |
| Free cash flow | -$9.81M | -$8.95M | n/a | -$30.99M |
| Cash & equivalents | $30.81M | $5.53M | $6.66M | $40.99M |
| Total assets | $45.60M | $9.51M | $84.18M | $45.92M |
| Total liabilities | $4.02M | n/a | $14.06M | $5.00M |
| Shareholders' equity | $41.59M | $5.59M | $70.12M | $40.92M |
| Return on year-end equity | -28.9% | -175.8% | -59.2% | -102.4% |
| Shares outstanding | 49.22M | 2.62M | 40.63M | n/a |
Revenue, most recent five fiscal years
| Fiscal year | Medicinova Inc | Can-Fite BioPharma Ltd. | Scienture Holdings, Inc. | Mereo BioPharma Group plc |
|---|---|---|---|---|
| Latest | $409.7K Ended 2025-12-31 | $405.0K Ended 2025-12-31 | $431.6K Ended 2025-12-31 | $500.0K Ended 2025-12-31 |
| 1 year earlier | n/a | $674.0K Ended 2024-12-31 | $136.6K Ended 2024-12-31 | $0 Ended 2024-12-31 |
| 2 years earlier | $1.00M Ended 2023-12-31 | $743.0K Ended 2023-12-31 | $1.36M Ended 2023-12-31 | $10.00M Ended 2023-12-31 |
| 3 years earlier | n/a | $810.0K Ended 2022-12-31 | $10.25M Ended 2022-12-31 | $0 Ended 2022-12-31 |
| 4 years earlier | $4.04M Ended 2021-12-31 | $853.0K Ended 2021-12-31 | $9.89M Ended 2021-12-31 | n/a |